MINDDful-XD research study
Summary
This study aims to figure out the connection between the digestive system and some brain-related conditions. The tiny organisms living in our digestive system, called gut microbiota. The gut microbiota might be linked to some brain-related conditions such as Autism, Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), and Tourette Syndrome (TS).
These conditions can be affected by both our genes and things around us in other words our environment. The gut microbiota can affect how our immune system grows. It also affects how our brain develops and functions. This is through a pathway called the gut-brain axis. Our team aims to see if there's a link between these conditions and the gut microbiota. We hope this research will lead us to new ways to support children and their families.
Eligibility
Eligible ages: 3 to 18
Accepts healthy participants: Yes
Inclusion criteria:
We are looking for interested families who,
1) live in Alberta
2) have a child between 3 to 18 years old
3) the child has these conditions. Healthy siblings who do not have these conditions are welcome too.
The whole study can be done from home. You will get a kit to collect a sample of your child's poop, then you will fill out some online questionnaires. Finally, you will have a short phone chat with a neurologist. Each child will get a $60 gift card when he/she completes the study.
Exclusion criteria:
The families who do not live in Alberta and who do not have a child between 3 to 18 years old with one of these conditions.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
minddfulxd@ucalgary.ca https://www.minddfulxd.ca
Principal investigator:
Davide Martino
Clinical trial:
No
REB-ID:
REB17-0693
External links